Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 5/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tinostamustine SCHEMBL29412228 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL12104079 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL7915764 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL24220325 | 0.96 | HDAC6 (0.93) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL15711929 | 0.96 | HDAC6 (0.92) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL15166327 | 0.95 | HDAC1 (0.91) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL12102557 | 0.92 | HDAC6 (0.85) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL16866939 | 0.92 | HDAC6 (0.85) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL16866938 | 0.92 | HDAC6 (0.85) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL7917346 | 0.92 | HDAC1 (0.85) | HDAC1HDAC6HDAC2HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310479-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | UNIV JOHNS HOPKINS (US) | 2023-10-05 | — | — | US | claimed |
| US-20220000840-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | HANGZHOU TINO PHARMA CO LTD (CN) | 2022-01-06 | — | — | US | claimed |
| US-20260083707-A1 | TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA | PURDUE PHARMA L.P. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250375424-A1 | TINOSTAMUSTINE FOR USE IN TREATING SARCOMA | PURDUE PHARMA LP (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250305055-A1 | PROGNOSTIC/PREDICTIVE BREAST CANCER SIGNATURE | CORNELL UNIVERSITY | 2025-10-02 | — | — | US | disclosed |
| EP-4612275-A2 | GENETICALLY ENGINEERED CELLS | Vertex Pharmaceuticals Incorporated (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12410190-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-2389375-B1 | HYDROXAMIC ACID DERIVATIVES | EURO CELTIQUE SA (LU) | 2015-05-20 | — | — | EP | disclosed |
| US-20150086551-A1 | Novel Therapeutic Agents | CRYSTAL BIOPHARMACEUTICAL LLC | 2015-03-26 | — | — | US | disclosed |
| US-20150086551-A1 | Novel Therapeutic Agents | CRYSTAL BIOPHARMACEUTICAL LLC | 2015-03-26 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2013040286-A2 | PHARMACEUTICAL COMPOSITIONS | EURO-CELTIQUE S.A. (LU) | 2013-03-21 | — | — | WO | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083707-A1 | TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA | MPL, SLC11A2, THPO | HDAC1 3771/4885HDAC6 3446/4885HDAC2 3718/4885 |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | HDAC1 4/4885HDAC6 7/4885HDAC2 8/4885 |
| US-20250375424-A1 | TINOSTAMUSTINE FOR USE IN TREATING SARCOMA | STAT6, ABL1, EWSR1 | HDAC1 3676/4885HDAC6 1829/4885HDAC2 3379/4885 |
| US-12410190-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2L10 | HDAC1 231/4885HDAC6 710/4885HDAC2 409/4885 |
| US-20220000840-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | SCN11A, SLC6A11, SLC5A11 | HDAC1 3603/4885HDAC6 3582/4885HDAC2 4317/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | HDAC1 7/4885HDAC6 12/4885HDAC2 15/4885 |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL9, BCL6 | HDAC1 1578/4885HDAC6 1622/4885HDAC2 2209/4885 |
| US-20150086551-A1 | Novel Therapeutic Agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC6 4/4885HDAC2 5/4885 |
| US-20260022345-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, CTNND1 | HDAC1 4554/4885HDAC6 4742/4885HDAC2 4747/4885 |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL2A1, BCL6 | HDAC1 1878/4885HDAC6 1824/4885HDAC2 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.